

CONSORT 2010 checklist of information to include when reporting a randomised trial*

Title and abstract 1a Identification as a parallel, double blind, placebo controlled, randomised trial 2 Ib Structured summary of trial design, methods, results and conclusions (for specific guidance see CONSORT for abstract) Introduction Background and objectives 2 Specific Background and explanation of rationale Objectives 2 Specific objectives and hypotheses Autorial design 3 Description of the trial design (such as parallel, factorial) including allocation ratio 7 Participants 4 Eligibility criteria for participants 5 Setting and locations where the data were collected Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were actually administrated Outcomes 6 Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed Any changes to trial outcomes after their trial commenced with reasons And How sample size was determined Randomisation: Sequence generation Allocation 9 Method used to generate the random allocation sequence generation Allocation 9 Methoanism used to implement the random allocation sequence describing any steps taken to conceal NA	Section/Topic	Item No	Checklist item	Reported on page No
Structured summary of trial design, methods, results and conclusions (for specific guidance see CONSORT for abstract) Introduction	Title and abstract			
Introduction Background and objectives 2b Specific Background and explanation of rationale Specific objectives and hypotheses 5-8 Methods Trial design 3a Description of the trial design (such as parallel, factorial) including allocation ratio 7 3b Important changes to methods after trial commencement with reasons 6 Participants 4a Eligibility criteria for participants 5 4b Setting and locations where the data were collected 6+24 Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were actually administrated Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed 6b Any changes to trial outcomes after their trial commenced with reasons NA Sample size 7a How sample size was determined 6 Tob Randomisation: Sequence 8a Method used to generate the random allocation sequence 6 generation 8b Type of randomisation; details of any restriction 6		1a	Identification as a parallel, double blind, placebo controlled, randomised trial	2
Sackground and objectives 2b Specific Background and explanation of rationale 2b Specific objectives and hypotheses 4-5 Methods Trial design 3a Description of the trial design (such as parallel, factorial) including allocation ratio 7 3b Important changes to methods after trial commencement with reasons 6 Participants 4a Eligibility criteria for participants 5 4b Setting and locations where the data were collected 6+24 Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were actually administrated 7 Sample size 7a How sample size was determined 6 Randomisation: Sequence 8a Method used to generate the random allocation sequence 6 Generation 8b Type of randomisation; details of any restriction 6 Methods 7b Pescription of the trial design (such as parallel, factorial) including allocation ratio 7 A-5 4-5 4-5 4-5 4-5 4-5 4-5 4-5		1b		2
Methods Trial design 3a Description of the trial design (such as parallel, factorial) including allocation ratio 7 3b Important changes to methods after trial commencement with reasons 8a Eligibility criteria for participants 4b Setting and locations where the data were collected 8a Method used to generate the random allocation sequence 9a Method used to generate the random allocation sequence 9a Method used to generate the random allocation sequence 9b Specific objectives and hypotheses 4-5 4-5 4-5 4-5 4-5 4-5 4-5 4-				
Methods Trial design 3a Description of the trial design (such as parallel, factorial) including allocation ratio 7 3b Important changes to methods after trial commencement with reasons 6 Participants 4a Eligibility criteria for participants 5 4b Setting and locations where the data were collected 6 +24 Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were actually administrated 7 Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed 6b Any changes to trial outcomes after their trial commenced with reasons NA How sample size was determined 6 Randomisation: Sequence 8a Method used to generate the random allocation sequence 6 generation 8b Type of randomisation; details of any restriction 6	•			
Trial design 3a Description of the trial design (such as parallel, factorial) including allocation ratio 7 3b Important changes to methods after trial commencement with reasons 6 Participants 4a Eligibility criteria for participants 5 4b Setting and locations where the data were collected 6 + 24 Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were actually administrated Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed 6b Any changes to trial outcomes after their trial commenced with reasons NA Sample size 7a How sample size was determined 6 7b Randomisation: Sequence 8a Method used to generate the random allocation sequence 7 Type of randomisation; details of any restriction 6	objectives	2b	Specific objectives and hypotheses	4-5
Participants 4a Eligibility criteria for participants 5 4b Setting and locations where the data were collected 6 + 24 Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were actually administrated Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed 6b Any changes to trial outcomes after their trial commenced with reasons NA Sample size 7a How sample size was determined 6 7b Randomisation: Sequence 8a Method used to generate the random allocation sequence 6 generation 8b Type of randomisation; details of any restriction 6	Methods			
Participants 4a Eligibility criteria for participants 4b Setting and locations where the data were collected Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were actually administrated Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed 6b Any changes to trial outcomes after their trial commenced with reasons 6a How sample size was determined 7b Randomisation: Sequence generation 8b Method used to generate the random allocation sequence Type of randomisation; details of any restriction 5 6 6 7 6 7 7 7 8 8 8 8 8 8 8 8 8 8 8 8 8	Trial design	3a	Description of the trial design (such as parallel, factorial) including allocation ratio	7
4b Setting and locations where the data were collected The interventions for each group with sufficient details to allow replication, including how and when they were actually administrated Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed 6b Any changes to trial outcomes after their trial commenced with reasons 7a How sample size was determined 7b NA Randomisation: Sequence generation 8a Method used to generate the random allocation sequence Type of randomisation; details of any restriction 6 +24 6 +24 6 +24 6 -24		3b	Important changes to methods after trial commencement with reasons	6
The interventions or each group with sufficient details to allow replication, including how and when they were actually administrated Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed 6b Any changes to trial outcomes after their trial commenced with reasons NA Sample size 7a How sample size was determined 7b Randomisation: Sequence generation 8a Method used to generate the random allocation sequence Type of randomisation; details of any restriction 5-6 NA 24-33 NA 6 NA 6 NA 6 NA	Participants	4a	Eligibility criteria for participants	5
they were actually administrated Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed 6b Any changes to trial outcomes after their trial commenced with reasons NA Sample size 7a How sample size was determined 7b Randomisation: Sequence generation 8a Method used to generate the random allocation sequence Type of randomisation; details of any restriction Completely defined pre-specified primary and secondary outcome measures, including how and when they are assessed NA Randomisation: Sequence generation Type of randomisation; details of any restriction	·	4b	Setting and locations where the data were collected	6 +24
they were assessed 6b Any changes to trial outcomes after their trial commenced with reasons Sample size 7a How sample size was determined 7b Randomisation: Sequence 9a Method used to generate the random allocation sequence 9a Type of randomisation; details of any restriction 100 100 100 100 100 100 100 1	Interventions	5		5-6
Sample size Any changes to trial outcomes after their trial commenced with reasons How sample size was determined 7b Randomisation: Sequence generation 8b Method used to generate the random allocation sequence generation Type of randomisation; details of any restriction NA NA NA NA NA O NA NA O NA NA	Outcomes	6a		24-33
Sample size 7a How sample size was determined 6 7b Randomisation: Sequence 8a Method used to generate the random allocation sequence 6 generation 8b Type of randomisation; details of any restriction 6		6b	•	NA
Randomisation: Sequence 8a Method used to generate the random allocation sequence 6 generation 8b Type of randomisation; details of any restriction 6	Sample size		• •	
Sequence 8a Method used to generate the random allocation sequence 6 generation 8b Type of randomisation; details of any restriction 6		7b		NA
generation 8b Type of randomisation; details of any restriction 6	Randomisation:			
<u></u>	Sequence	8a	·	6
Allocation 9 Mechanism used to implement the random allocation sequence describing any steps taken to conceal NA	generation	8b	Type of randomisation; details of any restriction	6
concealment the sequence until interventions were assigned		9	· · · · · · · · · · · · · · · · · · ·	NA

CONSORT 2010 checklist

mechanism			
Implementation 10 Who generated the random allocation sequence, who e		Who generated the random allocation sequence, who enrolled participants and who assigned to interventions	6
Blinding	11a	If done who was blinded after assignment to interventions and how	6
J	11b	If relevant, description of the similarity of interventions	NA
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	25-33
Results Participant 13a flow (a diagram is strongly recommended)	a/13b		5-6, 24-33
Recruitment	14a	Dates defining the periods of recruitment and follow up	6
	14b	Why the trial ended or was stopped	NA
Baseline data	15	A table showing the Demographic and clinical characteristics for each group	24
Numbers analysed	16	For each group number of participants included in each analysis and whether the analysis was by original assigned groups	
•	17a	For each primary and secondary outcome, the results for each group and the estimated effect have shown 95% confidence interval.	
Ancillary	17 b	NA	NA
analyses	18		NA
Harms	19	All important harms or unintend effects in each group	NA
Discussion	20	Trial limitations, addressing sources of potential bias, imprecision, and if relevant multiplicity of analyses	NA
Limitations			
Generalisability	21	Generalisability of the trial findings	NA
Interpretation	22		16-22

Other information	า		
Registration	23	Registration number and name of the trial	1 and 5
Protocol	24	Where the full trial protocol can be accessed if available	5
Funding	25	Sources of funding and other support, role of the funders	20

*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.

CONSORT 2010 checklist Page 3